Raloxifene
Evista, Raloxifene Hydrochloride
Estrogen Agonist/Antagonist
NADAC/unit
$0.2485
No Shortage
Tier 1: 20.7%
8 Manufacturers
8 ANDAs
Raloxifene hydrochloride is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in po....
vs. brand Evista: Generic saves up to 98% per unit
Generic Manufacturers
AMNEAL PHARMACEUTICALSAUROBINDO PHARMA LTDCADILA PHARMACEUTICALS LTDELI LILLY AND COGLENMARK PHARMACEUTICALS LTDINVAGEN PHARMACEUTICALS INCSCIEGEN PHARMACEUTICALS INCTEVA PHARMACEUTICALS USAWATSON LABORATORIES INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.